前十大流通股东累计持有： 15797.43万股，累计占流通股比： 41.39%，较上期变化： -126.77万 股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 厦门麦迪肯科技有限公司 | 13803.07 | 36.17 | 不变 | | 王珺 | 482.37 | 1.26 | 不变 | | 厦门三态科技有限公司 | 446.42 | 1.17 | 不变 | | 李田凤 | 247.12 | 0.65 | 0.26 | | 招商基金管理有限公司-社保基金1903组合 | 165.77 | 0.43 | 新进 | | 陈峰 | 145.00 | 0.38 | 新进 | | 王江平 | 135.68 | 0.36 | 不变 | | 邓山英 | 135.00 | 0.35 | 不变 | | MERRILL LYNCH INTERNATIONAL | 125.00 | 0.33 | 新进 | | 吴军芳 | 112.00 | 0.29 | -11.20 | | 较上个报告期退出前十大股东有 | | | | | 东方红中证 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2025-002 鹭燕医药股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 鹭燕医药股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日以邮件形式发出第六届 监事会第五次会议（以下简称"监事会"）通知，会议于 2025 年 4 月 20 日以现场方式在公 司八楼会议室举行。出席本次会议的监事共 3 人，占公司监事总数的 100%。本次会议由监 事会主席蔡梅桢女士主持，公司董事会秘书列席会议。本次会议的召集和召开符合《公司法》 和《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议《关于 2024 年度公司监事会工作报告的议案》； 表决结果：以同意 3 票、反对 0 票、弃权 0 票通过议案，同意票数占全体有表决权票数 比例 100%。 《鹭燕医药股份有限公司 2024 年度监事会工作报告》全文刊载于巨潮资讯网 （www.cninfo.com.cn）。 本议案尚需提交公司 2024 年年度股东大会审议。 （二）审议《关于公 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2025-001 表决结果：以同意 7 票、反对 0 票、弃权 0 票、回避 0 票通过议案，同意票数占全体有 表决权票数比例 100%。 （二）审议《关于 2024 年度公司董事会工作报告的议案》； 表决结果：以同意 7 票、反对 0 票、弃权 0 票、回避 0 票通过议案，同意票数占全体有 表决权票数比例 100%。 《鹭燕医药股份有限公司 2024 年度董事会工作报告》全文刊载于巨潮资讯网 （www.cninfo.com.cn）。公司独立董事叶少琴、宋培林、吴俊龙分别向董事会提交了《独立 董事 2024 年度述职报告》，并将在公司 2024 年年度股东大会上进行述职，报告全文刊载于 巨潮资讯网（www.cninfo.com.cn）。 鹭燕医药股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 鹭燕医药股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日以邮件形式发出第六届 董事会第五次会议（以下简称"董事会"）通知，会议于 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥20.47 billion, representing a 3.15% increase from ¥19.85 billion in 2023[15]. - The net profit attributable to shareholders for 2024 was approximately ¥345.64 million, a decrease of 4.92% compared to ¥363.53 million in 2023[15]. - The basic earnings per share for 2024 was ¥0.89, down 5.32% from ¥0.94 in 2023[15]. - The total assets at the end of 2024 were approximately ¥12.64 billion, an increase of 7.16% from ¥11.79 billion at the end of 2023[15]. - The net assets attributable to shareholders increased by 7.33% to approximately ¥3.16 billion from ¥2.95 billion at the end of 2023[15]. - The company reported a weighted average return on equity of 11.29%, down from 12.22% in 2023[15]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately ¥347.20 million, a slight increase of 0.33% from ¥346.05 million in 2023[15]. - The company achieved total revenue of CNY 2,047,076.61 million, a year-on-year increase of 3.15%[33]. - Net profit attributable to shareholders decreased by 4.92% to CNY 34,564.47 million, while the net profit excluding non-recurring gains and losses increased by 0.33% to CNY 34,720.37 million[33]. - The company reported a total revenue of 9,240 million for the period ending December 31, 2024, with a significant increase of 320.5 million compared to the previous period[101]. Cash Flow and Investments - The net cash flow from operating activities decreased by 55.89% to approximately ¥577.48 million from ¥1.31 billion in 2023[15]. - The total cash inflow from operating activities was approximately ¥22.33 billion in 2024, a slight increase of 0.88% from ¥22.13 billion in 2023[61]. - The total cash outflow from operating activities rose by 4.45% to ¥21.75 billion in 2024, compared to ¥20.82 billion in 2023[61]. - The company's investment activities generated a net cash flow of -¥369.73 million in 2024, an improvement of 30.79% from -¥534.24 million in 2023[62]. - The company has established a standardized fund allocation management system to enhance the efficiency of daily fund usage and ensure effective monitoring[43]. - The company has completed the acquisition of 100% equity in Ganzhou Luyuan Pharmaceutical, integrating the pharmacy into its operations[127]. Market Position and Strategy - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China in 2023, maintaining its position as the largest pharmaceutical distribution company in Fujian Province for 15 consecutive years[26]. - The company has expanded its market presence through acquisitions in regions such as Sichuan, Jiangxi, Hainan, and Hong Kong, enhancing its competitive edge[31]. - The pharmaceutical distribution industry is experiencing a transformation towards higher concentration and efficiency, driven by policy and market demand[29]. - The company aims to achieve 100% coverage of secondary and higher medical institutions in Fujian Province, which was accomplished in 2009[31]. - The company is actively exploring the application of artificial intelligence and big data in the healthcare service sector, indicating a focus on innovation[31]. - The company is focusing on the integration of high-value and low-value medical consumables, optimizing its business structure and expanding market space[34]. - The company is committed to compliance and risk management, aligning with national policies to enhance regulatory adherence[82]. - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its market position[102]. Operational Efficiency and Cost Management - The company reported a gross margin of 6.32% in the pharmaceutical wholesale sector, with a slight decrease of 0.23% compared to the previous year[50]. - In 2024, the total operating cost for pharmaceuticals was approximately ¥15.94 billion, accounting for 84.11% of total operating costs, reflecting a year-on-year increase of 4.21%[53]. - The company has implemented an effective information service system, utilizing real-time online platforms to provide instant order services to upstream and downstream clients[43]. - The company plans to enhance operational efficiency and market responsiveness through resource integration and strengthening scale advantages in response to increasing competition in the pharmaceutical distribution industry[76]. - The company aims to achieve a gross margin of 28% in 2024, up from 24% in the previous year[170]. Research and Development - Research and development expenses increased by 5.63% to ¥5.85 million in 2024, maintaining a ratio of 0.03% of operating revenue[60]. - The company is investing in new product development, with a budget allocation of 6,200 million for research and innovation in 2024[162]. - The company is focusing on R&D for new medical devices, with an investment of 1,000 million planned for 2024[166]. - Research and development expenditures are projected to increase by 27% in 2024, focusing on advanced technologies and product enhancements[171]. Governance and Compliance - The company has established a complete independent procurement, logistics, production, and sales system, ensuring no reliance on the controlling shareholder[97]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure are not provided[91]. - The company has established a remuneration management system linking executive pay to company performance[109]. - The company has not reported any major asset, personnel, or financial dependencies on the controlling shareholder[95]. - The company has established long-term commitments to avoid engaging in any competitive business activities with its subsidiaries[136]. User Engagement and Market Expansion - User data indicates a growth in active users, with projections estimating an increase to 5,000 million by March 2024[162]. - The company aims to achieve a user base of 5,000 by June 2024, representing a 20% increase from the previous year[166]. - The company is focusing on market expansion, targeting a 10% increase in market share in the Asia-Pacific region by 2025[176]. - A strategic partnership is being explored with a leading technology firm to leverage synergies and enhance product capabilities[171]. Risks and Challenges - The company faces intensified market competition due to the "two-invoice system" and "volume-based procurement" policies, which may impact its competitive advantage in the Fujian province pharmaceutical distribution industry[84]. - The company's gross profit is closely tied to drug prices, and ongoing price declines may compress profit margins if market share and sales volume do not increase as expected in provinces like Fujian, Sichuan, and Jiangxi[85]. - The company has a significant reliance on public hospitals as major clients, which poses risks related to accounts receivable management if payment delays occur[86]. - The company may face goodwill impairment risks if acquired companies do not perform as expected, potentially affecting overall financial results[88].

Financial Performance - The company's revenue for Q1 2025 was CNY 5,173,756,306.59, representing a 0.74% increase compared to CNY 5,135,680,997.86 in the same period last year[5] - Net profit attributable to shareholders decreased by 14.86% to CNY 71,323,645.12 from CNY 83,776,431.42 year-on-year[5] - Basic earnings per share fell by 18.18% to CNY 0.18 from CNY 0.22 in the same period last year[5] - Total operating revenue for the current period is approximately ¥5.17 billion, a slight increase from ¥5.14 billion in the previous period, representing a growth of about 0.3%[22] - Net profit for the current period is approximately ¥69.76 million, down from ¥83.52 million in the previous period, indicating a decrease of about 16.5%[23] - The company’s total comprehensive income for the current period is approximately ¥69.78 million, down from ¥83.53 million in the previous period, a decrease of about 16.5%[24] Cash Flow and Investments - The net cash flow from operating activities improved by 23.37%, reaching CNY -81,329,060.26 compared to CNY -106,133,464.90 in the previous year[5] - The net cash flow from investing activities improved by 54.21%, amounting to CNY -65,955,913.22 compared to CNY -144,025,906.71 in the previous year[10] - Cash flow from operating activities showed a net outflow of approximately ¥81.33 million, an improvement from a net outflow of ¥106.13 million in the previous period[25] - The company’s cash and cash equivalents at the end of the period stood at approximately ¥276.32 million, down from ¥308.54 million at the end of the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 12,628,639,470.41, a slight decrease of 0.08% from CNY 12,638,595,480.94 at the end of the previous year[5] - The company's current assets totaled CNY 9,833,468,783.15, compared to CNY 9,870,027,807.20 at the start of the period, indicating a decrease of approximately 0.37%[19] - The total liabilities of the company were CNY 9,366,337,106.38, down from CNY 9,446,689,554.59, representing a decrease of approximately 0.85%[20] - The company's total equity increased to CNY 3,262,302,364.03 from CNY 3,191,905,926.35, marking an increase of about 2.2%[21] - The company’s cash and cash equivalents decreased to CNY 457,879,572.29 from CNY 576,849,591.87, a decline of approximately 20.5%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,692[12] - The largest shareholder, Xiamen Meidiken Technology Co., Ltd., holds 35.53% of the shares, totaling 138,030,674 shares[12] Operational Metrics - The weighted average return on equity decreased to 2.23% from 2.80% year-on-year[5] - The company reported a significant reduction in receivables financing by 61.13%, down to CNY 15,110,744.01 from CNY 38,879,653.04[10] - The company’s inventory decreased to CNY 2,624,555,678.45 from CNY 2,864,755,977.45, a reduction of approximately 8.36%[18] - The company’s long-term borrowings stood at CNY 635,111,487.26, slightly down from CNY 648,408,776.05, indicating a decrease of about 2%[20] - The company's short-term borrowings increased to CNY 4,070,660,585.83 from CNY 3,874,674,322.37, reflecting an increase of about 5.5%[20] Research and Development - Research and development expenses increased to approximately ¥1.37 million from ¥1.22 million, marking a rise of about 12.9%[22] Legal Matters - The company has ongoing litigation to recover CNY 3,969.73 million from Guizhou Mingrun Construction Engineering Co., Ltd., with a court ruling awarding CNY 3,162.83 million[17] - The company received a total of CNY 78,005,000 from the bankruptcy asset distribution of Guizhou Dechangxiang Pharmaceutical Co., Ltd., with CNY 5,539,110.00 received by Huaron Yufu[15] Impairment and Losses - The company reported a decrease in investment income, with losses of approximately ¥5.06 million compared to losses of ¥3.55 million in the previous period[22] - The company experienced a decrease in credit impairment losses, which improved to approximately -¥8.76 million from -¥12.28 million in the previous period[23]

证券代码：002788 证券简称：鹭燕医药 公告编号：2024-029 鹭燕医药股份有限公司 关于为子公司提供担保的进展公告 二、担保进展情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 鹭燕医药股份有限公司（以下简称"鹭燕医药"或"公司"）于 2024 年 4 月 12 日、2024 年 5 月 7 日召开公司第六届董事会第二次会议、2023 年年度股东大会审议通过了《关于公 司申请综合授信额度及对子公司担保事项的议案》，同意公司（包括直接和间接控股的子公 司）向各银行或其他金融机构申请总额不超过人民币 200 亿元的综合授信额度，同时公司为 部分子公司申请贷款和采购货款付款提供担保，合计担保授信额度人民币 125 亿元。本次担 保及授权事项期限自公司 2023 年年度股东大会审议通过之日起不超过 12 个月。具体内容 请详见公司于 2024 年 4 月 16 日披露的《关于公司申请综合授信额度及对子公司担保事项 的公告》（公告编号：2024-007）。 | | | 有限 | 厦门 | | | | | | 担 | | --- | --- ...

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2024-005 | --- | --- | --- | |-----------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------| | | | √特定对象调研 □分析师会议 | | 投资者关系 | | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 | | 蓝马资本、广州顺从、金时资本、世纪量子、知远投资、图灵投 | | 及人员姓名 | | 资、湖北盛世、内蒙古博汇、恒天成基金、太空融基金等 | | 时间 | 2024 年 12 月 18 日 | 9:00-11:00 | | | | | | 地点 上市公司 | 鹭燕医药会议室 | | | 接待人员 ...

证券代码：002788 证券简称：鹭燕医药 公告编号：2024-028 一、股份减持计划实施情况 （一）已披露的减持计划的主要内容 鹭燕医药股份有限公司（以下简称"公司"）于 2024 年 8 月 16 日在《证券日报》《证券 时报》《中国证券报》及巨潮资讯网（http://www.cninfo.com.cn）发布了《关于公司部分 董事、高级管理人员股份减持计划的公告》（公告编号：2024-019），披露了公司部分董事、 高级管理人员股份减持计划（以下简称"本次减持计划"）。自公告之日（2024 年 8 月 16 日） 后十五个交易日起的三个月内，李卫阳先生、张珺瑛女士、朱明国先生、雷鸣先生拟通过集 中竞价、大宗交易等方式减持其持有的公司股份，其中：李卫阳先生拟减持股份数量不超过 1,009,136 股，即不超过公司总股本的 0.2597%；张珺瑛女士拟减持股份数量不超过 897,669 股，即不超过公司总股本的 0.2311%；朱明国先生拟减持股份数量不超过 250,000 股，即不 超过公司总股本的 0.0643%；雷鸣先生拟减持股份数量不超过 120,531 股，即不超过公司总 股本的 0.0310%。 ...

证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 编号：2024-004 | --- | --- | --- | |-------------------------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | 投资者关系 活动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 博时基金、东方证券 | | | 时间 | 2024 年 10 月 31 日 | 13:40-14:40 | | 地点 | 鹭燕医药会议室 | | | 上市公司 接待人员姓名 | | 董事会秘书叶泉青、证券事务专员林秋娴 | | | | 一、介绍公司基本概况、业务布 ...

Financial Performance - Revenue for Q3 2024 reached ¥15,413,532,406.63, an increase of 7.51% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 8.21% to ¥257,346,811.41[2] - Basic and diluted earnings per share both fell by 10.53% to ¥0.66[2] - Total operating revenue for the period reached ¥15,413,532,406.63, an increase of 4.3% compared to ¥14,775,163,931.09 in the previous period[13] - Net profit for the period was ¥257,901,103.73, slightly down from ¥259,059,315.29, indicating a decrease of 0.4%[14] - Earnings per share (EPS) for the period was ¥0.66, compared to ¥0.67 in the previous period[15] - The total comprehensive income for the period was ¥257,833,211.58, slightly down from ¥260,275,340.86 in the previous period[15] Cash Flow - Net cash flow from operating activities dropped significantly by 59.85% to ¥297,724,410.97[2] - Operating cash inflow for the current period reached ¥17,002,496,352.84, an increase of 1.83% from ¥16,695,347,747.84 in the previous period[16] - Net cash flow from operating activities decreased to ¥297,724,410.97, down 59.93% from ¥741,459,736.05 in the previous period[16] - Cash outflow from investment activities totaled ¥302,002,435.19, a decrease of 39.19% compared to ¥496,727,775.45 in the previous period[17] - Net cash flow from financing activities was -¥121,749,663.93, improving from -¥203,396,893.33 in the previous period[17] - The ending balance of cash and cash equivalents was ¥335,675,180.23, down from ¥445,463,828.70 in the previous period[17] - Cash received from operating activities included ¥16,773,182,605.57 from sales, up from ¥16,415,484,329.29 in the previous period[16] - Total cash outflow for operating activities was ¥16,704,771,941.87, an increase of 4.69% from ¥15,953,888,011.79 in the previous period[16] - Cash received from tax refunds was ¥1,937,751.84, an increase of 50.93% from ¥1,285,210.73 in the previous period[16] - Cash paid to employees was ¥427,648,935.85, slightly up from ¥417,505,100.09 in the previous period[16] - Cash inflow from financing activities was ¥7,100,151,424.33, an increase of 5.43% from ¥6,735,773,384.41 in the previous period[17] Assets and Liabilities - Total assets increased by 5.12% to ¥11,793,594,461.35 compared to the end of the previous year[2] - Total assets increased from 11.794 billion yuan to 12.397 billion yuan, an increase of approximately 5.1%[11] - Total liabilities rose from 8.817 billion yuan to 9.296 billion yuan, indicating an increase of about 5.4%[11] - Shareholders' equity attributable to shareholders rose by 4.27% to ¥2,946,258,377.95[2] - The total equity attributable to shareholders of the parent company increased to ¥3,072,155,028.62 from ¥2,946,258,377.95, representing a growth of 4.3%[12] - The company's total assets and equity reached ¥12,397,117,658.20 and ¥3,101,393,316.77 respectively, showing an increase from the previous year's figures[12] Investment and Expenses - Investment income for the year-to-date period decreased by 167.53% to -¥12,979,300[5] - Research and development expenses rose to ¥3,635,551.77, up from ¥2,835,211.85, marking a significant increase of 28.3%[13] - The company reported a decrease in investment income, with a loss of ¥12,979,289.94 compared to a loss of ¥4,851,615.76 in the previous period[14] - Other comprehensive income after tax was reported at -¥67,892.15, contrasting with a gain of ¥1,216,025.57 in the previous period[14] Legal and Operational Matters - The company initiated litigation against Guizhou Mingrun Construction Engineering Co., Ltd. for 39.6973 million yuan, with a court ruling awarding 31.6283 million yuan[9] - The company plans to continue pushing for the judicial auction of collateral to prioritize debt repayment[8] - The company signed new retail store lease contracts, resulting in a 46.38% increase in lease liabilities[5] - Cash flow from investing activities increased by 38.13% due to reduced expenditures on construction projects[5] - Chengdu Hechuang received a total of 7.8005 million yuan and 55.3911 million yuan from the bankruptcy estate of Guizhou Dechangxiang Pharmaceutical Co., Ltd. as part of the bankruptcy reorganization plan[8]